Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung Cancer
Paul Takam Kamga, Adrien Costantini, Claude Capron, Mathieu Glorion et autres
0 citationsCancer Immunology Immunotherapy
Paul Takam Kamga
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
66Publications signalées
1187Citations signalées
5Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchMesenchymal stem cell research
Publications récentes
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
Adrien Costantini, Paul Takam Kamga, Elvire Pons‐Tostivint, Delphine Fradin et autres
4 citationsCancer Immunology Immunotherapy
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)
Pierre Magdelaine, Adrien Costantini, Paul Takam Kamga, Christy Gaëlla Kotokpo Youkou et autres
0 citationsTranslational Lung Cancer Research
Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Assya Akli, Paul Takam Kamga, Catherine Julié, Claude Capron et autres
7 citationsCancer Immunology Immunotherapy
135P Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
Adrien Costantini, Paul Takam Kamga, Claude Capron, Emile Jf et autres
0 citationsAnnals of Oncology
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer
Paul Takam Kamga, M. Mayenga, Louise Sebane, Adrien Costantini et autres
10 citationsLung Cancer
1498P HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Assya Akli, Paul Takam Kamga, Adrien Costantini, Christy Gaëlla Kotokpo Youkou et autres
0 citationsAnnals of Oncology
1499P Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Etienne Giroux‐Leprieur, Paul Takam Kamga, M. Mayenga, Adrien Costantini et autres
0 citationsAnnals of Oncology
1496P Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Paul Takam Kamga, M. Mayenga, Louise Sebane, Adrien Costantini et autres
0 citationsAnnals of Oncology
Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
Giada Dal Collo, Paul Takam Kamga
2 citationsCancers
Editorial: Influence of potential diagnostic biomarkers in lung cancer
2 citationsFrontiers in Oncology
Data from Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia
Paul Takam Kamga, Giada Dal Collo, Martina Midolo, Annalisa Adamo et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.